Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million

Corporate Breaking News

Home : Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million

Aug 04 2022	Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million
AACHEN, Germany, Aug. 4, 2022 /PRNewswire/ -- Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal's investigational medicine Resiniferatoxin ("RTX"). Shionogi obtained the exclusive rights to commercialise Grünenthal's asset in Japan...


Source:https://www.prnewswire.com:443/news-releases/grunenthal-to-license-osteoarthritis-pain-treatment-to-shionogi-in-japan-in-deal-of-up-to---500-million-301599128.html

Related News
» F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim » Detect Technologies annonce la conclusion d'un accord mondial avec Vedanta